JP2018528783A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528783A5
JP2018528783A5 JP2018515456A JP2018515456A JP2018528783A5 JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5 JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5
Authority
JP
Japan
Prior art keywords
duplex
modified
modified oligonucleotide
extrahepatic
section
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053836 external-priority patent/WO2017053999A1/en
Publication of JP2018528783A publication Critical patent/JP2018528783A/ja
Publication of JP2018528783A5 publication Critical patent/JP2018528783A5/ja
Pending legal-status Critical Current

Links

JP2018515456A 2015-09-25 2016-09-26 コンジュゲートアンチセンス化合物及びその使用 Pending JP2018528783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233292P 2015-09-25 2015-09-25
US62/233,292 2015-09-25
PCT/US2016/053836 WO2017053999A1 (en) 2015-09-25 2016-09-26 Conjugated antisense compounds and their use

Publications (2)

Publication Number Publication Date
JP2018528783A JP2018528783A (ja) 2018-10-04
JP2018528783A5 true JP2018528783A5 (cg-RX-API-DMAC7.html) 2019-11-07

Family

ID=58387451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515456A Pending JP2018528783A (ja) 2015-09-25 2016-09-26 コンジュゲートアンチセンス化合物及びその使用

Country Status (4)

Country Link
US (2) US11116843B2 (cg-RX-API-DMAC7.html)
EP (1) EP3353306A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018528783A (cg-RX-API-DMAC7.html)
WO (1) WO2017053999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018056442A1 (ja) 2016-09-23 2018-03-29 国立大学法人東京医科歯科大学 血液脳関門通過型ヘテロ2本鎖核酸
CN111448308A (zh) 2017-08-03 2020-07-24 沃雅戈治疗公司 递送aav的组合物和方法
WO2019060432A2 (en) * 2017-09-19 2019-03-28 Children's National Medical Center GAPMERS AND METHODS OF USING THE SAME FOR THE TREATMENT OF MUSCLE DYSTROPHY
JP2021506239A (ja) * 2017-12-14 2021-02-22 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 複合アンチセンス化合物及びその使用
CN111819283A (zh) 2018-01-12 2020-10-23 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
MX2020008581A (es) 2018-02-21 2020-09-21 Bristol Myers Squibb Co Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
WO2019177061A1 (ja) 2018-03-14 2019-09-19 国立大学法人東京医科歯科大学 核酸複合体
WO2019181946A1 (ja) * 2018-03-19 2019-09-26 国立大学法人東京医科歯科大学 毒性が軽減した核酸
WO2019182294A1 (ko) * 2018-03-19 2019-09-26 주식회사 케이티 비디오 신호 처리 방법 및 장치
EP3770257A4 (en) * 2018-03-22 2022-03-09 National University Corporation Tokyo Medical and Dental University BHS-PASSING LIPID LIGAND OF A HETERONUCLEIC ACID
US20220064636A1 (en) * 2018-10-05 2022-03-03 Ionis Pharmaceuticals, Inc. Modified oligomeric compounds and uses thereof
SG11202110674XA (en) * 2019-03-29 2021-10-28 Mitsubishi Tanabe Pharma Corp Compound, method and pharmaceutical composition for modulating expression of dux4
WO2020209285A1 (ja) * 2019-04-08 2020-10-15 国立大学法人東京医科歯科大学 筋疾患治療用医薬組成物
WO2021054370A1 (ja) 2019-09-18 2021-03-25 国立大学法人東京医科歯科大学 核酸複合体
US20240117346A1 (en) * 2019-10-11 2024-04-11 National University Corporation Tokyo Medical And Dental University Modified hetero nucleic acids
CN114945669B (zh) * 2019-11-06 2025-01-10 阿尔尼拉姆医药品有限公司 肝外递送
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
EP4208174A4 (en) * 2020-09-04 2025-06-04 The University of Chicago Nucleic acid-derivatized therapeutics
EP4223875A1 (en) * 2020-09-30 2023-08-09 Nanopeptide (Qingdao) Biotechnology Ltd. Sirna of angiopoietin-like 3 (angptl3) and use thereof
US20240002853A1 (en) 2020-11-23 2024-01-04 Alpha Anomeric Sas Nucleic acid duplexes
AR124713A1 (es) * 2021-01-28 2023-04-26 Dicerna Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión de genes en el sistema nervioso central
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
JP2025512835A (ja) 2022-03-28 2025-04-22 エンピリコ インク. 修飾オリゴヌクレオチド
US20250304957A1 (en) 2022-05-13 2025-10-02 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
TW202508607A (zh) * 2023-05-19 2025-03-01 大陸商北京炫景瑞醫藥科技有限公司 雙股寡核苷酸及其共軛物和用途
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
CA2619534A1 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
WO2009082606A2 (en) * 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Folate conjugates
US20100048676A1 (en) * 2008-08-04 2010-02-25 University Of Rochester Non-androgen dependent roles for androgen receptor in liver cancer
US20100222417A1 (en) * 2008-11-26 2010-09-02 Alnylam Pharmaceuticals Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
KR101900770B1 (ko) 2010-07-19 2018-09-20 아이오니스 파마수티컬즈, 인코포레이티드 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
US9580708B2 (en) * 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
CN104126010B (zh) 2011-12-16 2021-04-06 国立大学法人东京医科齿科大学 嵌合的双链核酸
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
JP6440170B2 (ja) 2013-03-01 2018-12-19 国立大学法人 東京医科歯科大学 キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
KR102138781B1 (ko) 2013-05-01 2020-07-28 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
EP3004347B1 (en) 2013-05-30 2018-09-26 National University Corporation Tokyo Medical and Dental University Double-stranded agents for delivering therapeutic oligonucleotides
AU2014282666A1 (en) 2013-06-16 2016-01-07 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
WO2015183943A2 (en) * 2014-05-27 2015-12-03 Trustees Of Boston University Inhibitors of fibroproliferative disorders and cancer
EP3686279B1 (en) * 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
EP3353305A4 (en) 2015-09-25 2019-09-18 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use

Similar Documents

Publication Publication Date Title
JP2018528783A5 (cg-RX-API-DMAC7.html)
US11116843B2 (en) Conjugated antisense compounds and their use
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
JP5763539B2 (ja) 5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
US9428750B2 (en) Oligomeric compounds comprising tricyclic nucleosides and methods for their use
RU2015151199A (ru) Сопряженные антисмысловые соединения и их применение
CN110846316B (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
CN114025848A (zh) 用于调节剪接和翻译的方法和组合物
JP2021072862A (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
US20160186175A1 (en) Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US9249178B2 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
KR20200104347A (ko) 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
US20250263703A1 (en) Linkage Modified Oligomeric Compounds
WO2021157730A1 (ja) 核酸医薬とその使用
US20220098595A1 (en) Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their use
JPWO2021030213A5 (cg-RX-API-DMAC7.html)
US20230089502A1 (en) Products and compositions
JP6934695B2 (ja) 核酸医薬とその使用
JP2023531249A (ja) Fubp1発現を調節するための増強されたオリゴヌクレオチド
CN117813383B (zh) 用于抑制CIDEB基因表达的siRNA、药物及其应用
US20250368998A1 (en) Nucleotide analogues, and preparation and application thereof
WO2020044349A1 (en) Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules
DE102022124232A1 (de) Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms
JP2024505583A (ja) Rtel1発現を阻害するための増強されたオリゴヌクレオチド
CN120060245A (zh) 一种siRNA抗体偶联物及其用途